Methylphenidate Hcl Solution
NDC Package 39328-154-50
Package Information
Methylphenidate Hcl solution is attention Deficit Disorders, NarcolepsyAttention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.Methylphenidate hcl oral solution is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. This formulation utilizes a solution delivery system. Marketed by Patrin Pharma, Inc., this product is identified by NDC 39328-154 and is authorized under FDA application ANDA210764.
Identification & Billing
- RxCUI: 1091133 - methylphenidate HCl 10 MG in 5 mL Oral Solution
- RxCUI: 1091133 - methylphenidate hydrochloride 2 MG/ML Oral Solution
- RxCUI: 1091133 - methylphenidate HCl 10 MG per 5 ML Oral Solution
- RxCUI: 1091133 - methylphenidate hydrochloride 10 MG per 5 ML Oral Solution
- RxCUI: 1091341 - methylphenidate HCl 5 MG in 5 mL Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 39328 - Patrin Pharma, Inc.
- 39328-154 - Methylphenidate Hcl
- 39328-154-50 - 500 mL in 1 BOTTLE
- 39328-154 - Methylphenidate Hcl
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 39328-154-50 identifies a specific commercial package of 500 ml in 1 bottle of Methylphenidate Hcl, a human prescription drug labeled by Patrin Pharma, Inc.. This solution is formulated for oral use and contains methylphenidate hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Patrin Pharma, Inc. on April 23, 2020. The current certification is valid through December 31, 2026.
How is this Patrin Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 39328015450. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.